145 Characterization of Adverse Reactions in Patients with Advanced Endometrial Cancer (Aec) Receiving Lenvatinib + Pembrolizumab (Study 309/Keynote-775)
AuthID
P-00V-TAT
P-00V-TAT
© 2024 CRACS & Inesc TEC - All Rights Reserved Privacy Policy | Terms of Service